Welcome to our dedicated page for DURECT news (Ticker: DRRX), a resource for investors and traders seeking the latest updates and insights on DURECT stock.
The DURECT Corporation (DRRX) news feed on Stock Titan aggregates historical company announcements, clinical updates, financial disclosures and transaction-related communications for this former Nasdaq-listed biopharmaceutical issuer. DURECT has described itself as a late-stage biopharmaceutical company focused on epigenetic therapies that target dysregulated DNA methylation, with particular emphasis on serious and life-threatening conditions such as alcohol-associated hepatitis (AH) and other forms of acute organ injury.
News items for DRRX include detailed updates on the development of the company’s lead investigational drug candidate, larsucosterol. These releases cover milestones such as the Phase 2b AHFIRM trial results, publication of data in NEJM Evidence, presentations at major liver disease meetings, and plans for a registrational Phase 3 trial in severe AH. Company communications also highlight that larsucosterol has received Fast Track and Breakthrough Therapy designations from the U.S. Food and Drug Administration for the treatment of AH.
The feed also captures DURECT’s corporate and portfolio developments, including announcements about its FDA-approved non-opioid analgesic POSIMIR, based on the SABER platform technology, and the sale of the ALZET osmotic pump product line. In 2025, a significant portion of the news flow relates to the tender offer and merger under which a subsidiary of Bausch Health Americas, Inc. agreed to acquire all outstanding shares of DURECT, followed by completion of the merger and subsequent delisting and deregistration of DRRX.
Investors and researchers can use this page to review historical earnings releases, business updates, clinical trial communications and acquisition-related announcements that together document DURECT’s evolution from a publicly traded company to an indirect wholly owned subsidiary within a larger pharmaceutical group.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
DURECT Corporation (NASDAQ: DRRX) announced that Dr. James Brown, President and CEO, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at 10:00 AM Eastern Time. The event is hosted by Ed Arce, Managing Director at H.C. Wainwright & Co. The session will cover DURECT's innovative therapies aimed at treating acute organ injury and chronic liver diseases, including the lead candidate Larsucosterol (DUR-928), which has received FDA Fast Track Designation for severe alcohol-associated hepatitis (SAH). A webcast of the chat will be available on DURECT's website, with a replay accessible for 90 days.
DURECT is focused on transforming treatments for liver diseases and has also licensed the FDA-approved POSIMIR for commercialization by Innocoll Pharmaceuticals in the United States.
DURECT Corporation (NASDAQ: DRRX) announced the acceptance of additional data from its Phase 2a trial evaluating larsucosterol for alcohol-associated hepatitis (AH), which will be published in the American Journal of Gastroenterology. The trial demonstrated a 100% survival rate among 19 patients during a 28-day follow-up, significantly better than the historical mortality rate of 26% in similar patients. The drug was well-tolerated across three doses and showed rapid improvements in liver biomarkers. Furthermore, the company is on track to report data from its ongoing Phase 2b AHFIRM trial in the second half of 2023, targeting 300 patients for further validation of larsucosterol's efficacy. With FDA Fast Track Designation, the company aims to expedite the drug's development to address an urgent medical need, as no FDA-approved therapies currently exist for AH.
DURECT Corporation (NASDAQ: DRRX) announced the appointment of Gail Maderis as the new Chair of the Board, effective March 17, 2023. She takes over from David Hoffmann, who will retire on June 21, 2023. Maderis has been a board member since January 2021, contributing to audit and compensation committees. The leadership change comes at a pivotal time for DURECT as it anticipates top-line data from its AHFIRM trial later this year. Maderis brings extensive biopharmaceutical experience, having previously led various organizations and currently serving as President and CEO of Antiva Biosciences.
DURECT Corporation (Nasdaq: DRRX) announced that CEO Dr. James Brown and management will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023. The discussion will be accessible from 2:00 to 2:20 PM Eastern Time and will cover DURECT's innovative therapies, including larsucosterol and POSIMIR. Larsucosterol is in clinical development for alcohol-associated hepatitis, with FDA Fast Track Designation. A webcast link for the presentation will be available on DURECT's website, with a replay available for 90 days. The press release includes forward-looking statements regarding future trials and commercialization efforts.
DURECT Corporation (Nasdaq: DRRX) reported financial results for Q4 and FY 2022, with total revenues of $3.3 million for Q4, down from $7.3 million a year prior. The net loss increased to $10.5 million compared to $7.0 million in Q4 2021. For the full year, revenues were $19.3 million with a net loss of $35.3 million. Cash holdings decreased to $43.6 million from $70.0 million year-over-year. The company is on track to complete enrollment in the AHFIRM trial in Q2 2023, with topline data expected in the latter half of the year, which may allow for potential FDA discussions regarding a New Drug Application (NDA) for Larsucosterol.
FAQ
What is the current stock price of DURECT (DRRX)?
What is the market cap of DURECT (DRRX)?
